Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide

Published Date: 31/01/2011
Category: Therapies & Markets

Research Report Decription

Sample Pages:

Click here (PDF)

Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) Pharmaceuticals industry. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

• Contains an executive summary and data on value, volume and segmentation
• Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
• Incorporates in-depth five forces competitive environment analysis and scorecards
• Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country. 
• Includes a five-year forecast of the industry

Key Questions Answered:

• Spot future trends and developments
• Inform your business decisions
• Add weight to presentations and marketing materials
• Save time carrying out entry-level research

Companies Mentioned:

Aché Laboratórios Farmacêuticos S.A., AstraZeneca, Cipla Ltd, EMS Sigma Pharma , GlaxoSmithKline, Novartis AG, Pfizer, Priamal healthcare Ltd, Rabaxy Laboratories Ltd, Sanofi-Aventis, Yangtze River Pharmaceutical Group

Paper Highlights:

• Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the pharmaceuticals industry and had a total market value of $63.7 Billion in 2010. China was the fastest growing country with a CAGR of 17.2% over the 2006–10 period.
• China is the leading country among the BRIC nations with market revenues of $25.7 Billion in 2010.
• China is expected to lead the pharmaceuticals industry in the BRIC nations with a value of $48.8, Billion in 2015